Glucose conjugation for the specific targeting and treatment of cancer
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Cancers of diverse origins exhibit marked glucose avidity and high rates of aerobic glycolysis. Increased understanding of this dysfunctional metabolism known as the Warburg effect has led to an interest in targeting it for cancer therapy. One promising strategy for such targeting is glycoconjugation, the linking of a drug to glucose or another sugar. This review summarizes the most salient examples of glycoconjugates, in which known cytotoxins or targeted anticancer therapeutics have been linked to glucose (or another glucose transporter substrate sugar) for improved cancer targeting and selectivity. Building on these examples, this review also provides a series of guidelines for the design and mechanistic evaluation of future glycoconjugates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Today this phenomenon is known as the Warburg effect and is recognized as one of the hallmarks of cancer [3].”
BackgroundWarburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“Almost a century ago, the German scientist Otto Warburg observed that cancerous tissues consume large amounts of glucose compared to non-transformed tissue and have high rates of aerobic glycolysis [1, 2].”
BackgroundThe metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416 · cited 1×
“Almost a century ago, the German scientist Otto Warburg observed that cancerous tissues consume large amounts of glucose compared to non-transformed tissue and have high rates of aerobic glycolysis [1, 2].”
BackgroundTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 1×
“Another antibody-drug conjugate, Kadcyla (trastuzumab emtansine; Figure 2b), received US FDA approval in February 2013 for the treatment of HER2-positive breast cancer following the EMILIA clinical trial [15].”
BackgroundTargeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411 · cited 1×
“Most efforts have focused on using small molecules to inhibit the function of metabolic enzymes, as comprehensively reviewed elsewhere [10, 11].”
BackgroundParker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197 · cited 1×
“For this reason, folate receptor α (FR-α) is overexpressed in an estimated 40% of human cancers (it is expressed only by certain types of epithelial cells in healthy individuals) [17, 18].”
BackgroundDe Vivo, D. C., Trifiletti, R. R., Jacobson, R. I., Ronen, G. M., Behmand, R. A., & Harik, S. I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109053251006 · Cited by 800 · cited 1×
“Incidentally, humans born with a mutated, functionallyimpaired GLUT-1 transporter experience a severe phenotype known as De Vivo disease which results in mental retardation, seizures, and a host of neurological deficits, underscoring the importance of GLUT-1 in supplying glucose to the nervous system [95].”
BackgroundSenter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763 · cited 1×
“Adcertis is thought to enter cancer cells via CD30 receptor-mediated endocytosis and subsequently be trafficked to endosomes, where a combination of degradative enzymes and increased acidity lead to cleavage to the active tubulin inhibitor [14].”
BackgroundGenes of glycolysis are ubiquitously overexpressed in 24 cancer classes
Altenberg, B., & Greulich, K. O. (2004) · Genomics · doi:10.1016/j.ygeno.2004.08.010 · Cited by 659 · cited 1×
“Glycolytic enzymes, as well as the insulinindependent glucose transporter GLUT-1, are widely overexpressed in human cancers [4, 5], and high expression levels of these proteins in tumor biopsy samples correlate with poor cancer prognosis, making them attractive therapeutic targets [6–9].”
BackgroundFolate-targeted therapeutic and imaging agents for cancer
Low, P. S., & Kularatne, S. A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.022 · Cited by 585 · cited 1×
“For this reason, folate receptor α (FR-α) is overexpressed in an estimated 40% of human cancers (it is expressed only by certain types of epithelial cells in healthy individuals) [17, 18].”
Background
Research works printed but not linked: 6
- Herrmann, 2011, Q. J. Nucl. Med. Mol. Imag., 55, 620
- Dosio, 2010, Curr. Opin. Invest. Drugs, 11, 1424
- Palit, 2005, Oncol. Rep., 14, 909
- Stewart, 2008, Oncol. Rep., 20, 1561
- Kerbusch, 2001, Drug Metab. Dispos., 29, 967
- Reske, 1997, J. Nucl. Med., 38, 1344
Cited by
Cu-Catalyzed Click Reaction in Carbohydrate Chemistry
Tiwari, V. K., Mishra, B. B., Mishra, K. B., Mishra, N., Singh, A. S., & Chen, X. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00408 · Cited by 862
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Glycosylation: mechanisms, biological functions and clinical implications
He, M., Zhou, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01886-1 · Cited by 499
Cu(I)-Catalyzed Click Chemistry in Glycoscience and Their Diverse Applications
Agrahari, A. K., Bose, P., Jaiswal, M. K., Rajkhowa, S., Singh, A. S., Hotha, S., Mishra, N., & Tiwari, V. K. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00920 · Cited by 472
Gold nanoparticles for cancer radiotherapy: a review
Haume, K., Rosa, S., Grellet, S., Śmiałek, M. A., Butterworth, K. T., Solov’yov, A. V., Prise, K. M., Golding, J., & Mason, N. J. (2016) · Cancer Nanotechnology · doi:10.1186/s12645-016-0021-x · Cited by 445
“As mentioned above, NPs below 5 nm are often used for radiosensitisation purposes due to the relatively rapid elimination from the body, good uptake, and favourable interaction with radiation, but at these sizes AuNPs can become chemically reactive (Alkilany and Murphy 2010; Ionita et al.”
A comprehensive review of glycosylated bacterial natural products
Elshahawi, S. I., Shaaban, K. A., Kharel, M. K., & Thorson, J. S. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00426d · Cited by 439
Molecular basis of ligand recognition and transport by glucose transporters
Deng, D., Sun, P., Yan, C., Ke, M., Jiang, X., Xiong, L., Ren, W., Hirata, K., Yamamoto, M., Fan, S., et al. (2015) · Nature · doi:10.1038/nature14655 · Cited by 384
Zhang, R., Qin, X., Kong, F., Chen, P., & Pan, G. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1582730 · Cited by 363
“Calvaresi et al. summarized structure-activity relationship of D-glucose as a substrate for the GLUT1 transporter (Figure 2(B)) (Calvaresi & Hergenrother, 2013).”
BackgroundImprovement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318
Prodrugs in medicinal chemistry and enzyme prodrug therapies
Walther, R., Rautio, J., & Zelikin, A. N. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.013 · Cited by 288
Moradi, S. V., Hussein, W. M., Varamini, P., Simerska, P., & Toth, I. (2016) · Chemical Science · doi:10.1039/c5sc04392a · Cited by 286
8-Hydroxyquinolines in medicinal chemistry: A structural perspective
Oliveri, V., & Vecchio, G. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.007 · Cited by 281
Iron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268
“Supported by the widespread clinical use of radiolabeled glucose analogs for tumor visualization by positron emission tomography (PET) [155], glycoconjugation is undergoing intense scrutiny as a method to increase specificity of anti-proliferative agents [156].”
BackgroundTargeting T cell metabolism for therapy
O'Sullivan, D., & Pearce, E. L. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.004 · Cited by 254
“One potential way to target T cell populations might be through transporter-facilitated drug uptake, whereby a metabolite is conjugated to a drug to enhance delivery into a target cell population [116].”
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer
Varghese, E., Samuel, S. M., Líšková, A., Samec, M., Kubatka, P., & Büsselberg, D. (2020) · Cancers · doi:10.3390/cancers12082252 · Cited by 208
“, glufosfamide and 2-DG-conjugated paclitaxel) [223,224].”
Tumor Abnormality-Oriented Nanomedicine Design
Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 188
Stimulus-cleavable chemistry in the field of controlled drug delivery
Xue, Y., Bai, H., Peng, B., Fang, B., Baell, J., Li, L., Huang, W., & Voelcker, N. H. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01061h · Cited by 173
Recent advances in iron complexes as potential anticancer agents
Wani, W. A., Baig, U., Shreaz, S., Shiekh, R. A., Iqbal, P. F., Jameel, E., Ahmad, A., Mohd-Setapar, S. H., Mushtaque, M., & Ting Hun, L. (2016) · New Journal of Chemistry · doi:10.1039/c5nj01449b · Cited by 165
1,8-Naphthalimide based fluorescent sensors for enzymes
Geraghty, C., Wynne, C., & Elmes, R. B. P. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213713 · Cited by 164
Patra, M., Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201510551 · Cited by 160
Triptolide: reflections on two decades of research and prospects for the future
Tong, L., Zhao, Q., Datan, E., Lin, G.-Q., Minn, I., Pomper, M. G., Yu, B., Romo, D., He, Q., & Liu, J. O. (2021) · Natural Product Reports · doi:10.1039/d0np00054j · Cited by 161
Recent progress in multifunctional metal chelators as potential drugs for Alzheimer's disease
Santos, M. A., Chand, K., & Chaves, S. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.04.013 · Cited by 159
Triptolide: Medicinal chemistry, chemical biology and clinical progress
Hou, W., Liu, B., & Xu, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.032 · Cited by 145
Patra, M., Awuah, S. G., & Lippard, S. J. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b06937 · Cited by 145
Designing polymers with sugar-based advantages for bioactive delivery applications
Zhang, Y., Chan, J. W., Moretti, A., & Uhrich, K. E. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.053 · Cited by 150
“Active targeting via sugar recognition by cancer cells The Warburg effect, where malignant cells have an accelerated metabolism and high glucose requirements compared to non-malignant cells, has been well-established in cancer pathology [106].”
BackgroundBarbosa, A. M., & Martel, F. (2020) · Cancers · doi:10.3390/cancers12010154 · Cited by 135
Direct synthesis of unprotected aryl C-glycosides by photoredox Ni-catalysed cross-coupling
Zhang, C., Xu, S., Zuo, H., Zhang, X., Dang, Q.-D., & Niu, D. (2023) · Nature Synthesis · doi:10.1038/s44160-022-00214-1 · Cited by 133
Advancing engineering design strategies for targeted cancer nanomedicine
Gomerdinger, V. F., Nabar, N., & Hammond, P. T. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-025-00847-2 · Cited by 146
“Cancer cells have high metabolic demand for glucose 173,174 , whereas immune cells express sugar-binding lectin receptors, which can be targeted with various sugars such as mannose and galactose 170–172 .”
A chemical perspective on the clinical use of platinum-based anticancer drugs
Alassadi, S., Pisani, M. J., & Wheate, N. (2022) · Dalton Transactions · doi:10.1039/d2dt01875f · Cited by 135
Glycosidase activated prodrugs for targeted cancer therapy
Martin, H., Lázaro, L. R., Gunnlaugsson, T., & Scanlan, E. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00379a · Cited by 136
Green Toxicology: a strategy for sustainable chemical and material development
Crawford, S. E., Hartung, T., Hollert, H., Mathes, B., van Ravenzwaay, B., Steger-Hartmann, T., Studer, C., & Krug, H. F. (2017) · Environmental Sciences Europe · doi:10.1186/s12302-017-0115-z · Cited by 124
Developments in Carbohydrate-Based Cancer Therapeutics
Hossain, F., & Andreana, P. R. (2019) · Pharmaceuticals · doi:10.3390/ph12020084 · Cited by 134
“discussed the glycoconjugation of some active cancer therapeutics [11].”
BackgroundInfluentialOrgano-tin antitumor compounds: Their present status in drug development and future perspectives
Arjmand, F., Parveen, S., Tabassum, S., & Pettinari, C. (2014) · Inorganica Chimica Acta · doi:10.1016/j.ica.2014.07.066 · Cited by 120
Ma, J., Wang, Q., Huang, Z., Yang, X., Nie, Q., Hao, W., Wang, P. G., & Wang, X. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00433 · Cited by 107
Sharma, R. B., Liaw, K., Sharma, A., Jimenez, A. S., Chang, M., Salazar, S., Amlani, I., Kannan, S., & Kannan, R. M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.018 · Cited by 106
Vasudevan, U. M., & Lee, E. Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107550 · Cited by 116
Dong, Q., Yang, B., Han, J.-G., Zhang, M., Liu, W., Zhang, X., Yu, H., Liu, Z., Zhang, S., Li, T., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.031 · Cited by 102
Suzuki, K., Miura, Y., Mochida, Y., Miyazaki, T., Toh, K., Anraku, Y., Melo, V., Liu, X., Ishii, T., Nagano, O., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.021 · Cited by 95
Peptide‐Coated Platinum Nanoparticles with Selective Toxicity against Liver Cancer Cells
Shoshan, M. S., Vonderach, T., Hattendorf, B., & Wennemers, H. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201813149 · Cited by 86
Historical perspective of tumor glycolysis: A century with Otto Warburg
Bononi, G., Masoni, S., Bussolo, V. D., Tuccinardi, T., Granchi, C., & Minutolo, F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.003 · Cited by 98
Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation
He, Q., Minn, I., Wang, Q., Xu, P. H., Head, S. A., Datan, E., Yu, B., Pomper, M. G., & Liu, J. O. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201606121 · Cited by 84
Self-assembled levan nanoparticles for targeted breast cancer imaging
Kim, S. J., Bae, P. K., & Chung, B. H. (2014) · Chemical Communications · doi:10.1039/c4cc07679f · Cited by 81
Multi-functional vesicles for cancer therapy: The ultimate magic bullet
Tavano, L., & Muzzalupo, R. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.07.060 · Cited by 84
Calatrava‐Pérez, E., Bright, S. A., Achermann, S., Moylan, C., Senge, M. O., Veale, E. B., Williams, D. C., Gunnlaugsson, T., & Scanlan, E. M. (2016) · Chemical Communications · doi:10.1039/c6cc06451e · Cited by 77
Belmonte‐Reche, E., Martínez‐García, M., Guédin, A., Zuffo, M., Arévalo‐Ruiz, M., Doria, F., Campos‐Salinas, J., Maynadier, M., Lopez-Rubio, J.-J., Freccero, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01672 · Cited by 77
Anticancer agents interacting with membrane glucose transporters
Granchi, C., Fortunato, S., & Minutolo, F. (2016) · MedChemComm · doi:10.1039/c6md00287k · Cited by 72
Glycoconjugates for glucose transporter-mediated cancer-specific targeting and treatment
Fu, J., Yang, J., Seeberger, P. H., & Yin, J. (2020) · Carbohydrate Research · doi:10.1016/j.carres.2020.108195 · Cited by 79
Application of glycosylation in targeted drug delivery
Chen, F., & Huang, G. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111612 · Cited by 70
Liu, C., Hsu, Y., Lee, J.-J., Chen, M., Lin, C., Huang, S., & Cheng, S. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110595 · Cited by 65
Lameijer, L. N., Hopkins, S. L., Brevé, T. G., Askes, S. H. C., & Bonnet, S. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201603066 · Cited by 63
Spatially resolved microfluidic stimulation of lymphoid tissue ex vivo
Ross, A. E., Belanger, M. C., Woodroof, J. F., & Pompano, R. R. (2017) · The Analyst · doi:10.1039/c6an02042a · Cited by 63
Krawczyk, M., Pastuch-Gawołek, G., Mrozek‐Wilczkiewicz, A., Kuczak, M., Skonieczna, M., & Musioł, R. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.11.047 · Cited by 71
Triptolide-targeted delivery methods
Xu, H., & Liu, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.058 · Cited by 64
Overview of Morin and Its Complementary Role as an Adjuvant for Anticancer Agents
Solairaja, S., Andrabi, M. Q., Dunna, N. R., & Venkatabalasubramanian, S. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1778747 · Cited by 59
“D-Glucose is the most usual sugar residue preferred as conjugate (26).”
BackgroundExploring Carbohydrates for Therapeutics: A Review on Future Directions
Wang, J., Zhang, Y., Lu, Q., Xing, D., & Zhang, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.756724 · Cited by 77
“Furthermore, carbohydrates (glucose or other glucose transporter substrates) have been conjugated to cytotoxins or anticancer therapeutics for the specific targeting and treatment of cancer (Calvaresi and Hergenrother, 2013).”
BackgroundArévalo‐Ruiz, M., Doria, F., Belmonte‐Reche, E., Rache, A. D., Campos‐Salinas, J., Lucas, R., Falomir, E., Cardá, M., Pérez-Victoria, J. M., Mergny, J., et al. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604886 · Cited by 57
Chen, J., Ji, Y., Feng, Q., Miao, X., Dou, B., & Wang, P. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112955 · Cited by 57
Dual Targeting of the Warburg Effect with a Glucose‐Conjugated Lactate Dehydrogenase Inhibitor
Calvaresi, E. C., Granchi, C., Tuccinardi, T., Bussolo, V. D., Huigens, R. W., Lee, H. Y., Palchaudhuri, R., Macchia, M., Martinelli, A., Minutolo, F., et al. (2013) · ChemBioChem · doi:10.1002/cbic.201300562 · Cited by 58
Sztandera, K., Działak, P., Marcinkowska, M., Stańczyk, M., Gorzkiewicz, M., Janaszewska, A., & Klajnert‐Maculewicz, B. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2673-9 · Cited by 57
“Such formulations have been shown to provide enhanced cytotoxicity and specific tumor accumulation, at the same time reducing systemic toxicity (16,21,22).”
BackgroundCarbohydrate-Appended Tumor Targeting Iron(III) Complexes Showing Photocytotoxicity in Red Light
Basu, U., Khan, I., Hussain, A., Gole, B., Kondaiah, P., & Chakravarty, A. R. (2014) · Inorganic Chemistry · doi:10.1021/ic4028173 · Cited by 55
Luo, X., & Liu, J. (2021) · Advanced Science · doi:10.1002/advs.202103971 · Cited by 55
Synthesis and Biological Testing of Novel Glucosylated Epigallocatechin Gallate (EGCG) Derivatives
Zhang, X., Wang, J., Hu, J., Huang, Y., Wu, X., Zi, C., Wang, X., & Sheng, J. (2016) · Molecules · doi:10.3390/molecules21050620 · Cited by 50
“Recently, preparation of glycoconjugates of small molecule drugs has become an attractive strategy in order to overcome problems of water solubility and stability in aqueous solution and reduce side effects [26,27].”
Madan, M., Patel, A., Skruber, K., Geerts, D., Altomare, D. A., & Phanstiel, O. (2016) · PubMed Central · Cited by 49
Yoon, H. Y., Shin, M. L., Shim, M. K., Lee, S., Na, J. H., Koo, H., Lee, H., Kim, J.-H., Lee, K. Y., Kim, K., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01083 · Cited by 50
Yu, N., Liu, T., Zhang, X., Gong, N., Ji, T., Chen, J., Liang, X., Kohane, D. S., & Guo, S. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01973 · Cited by 49
Glycoconjugated Metal Complexes as Cancer Diagnostic and Therapeutic Agents
Bononi, G., Iacopini, D., Cicio, G., Pietro, S. D., Granchi, C., Bussolo, V. D., & Minutolo, F. (2020) · ChemMedChem · doi:10.1002/cmdc.202000456 · Cited by 49
Programmable selective acylation of saccharides mediated by carbene and boronic acid
Lv, W., Chen, H., Zhang, X., Ho, C. C., Liu, Y., Wu, S., Wang, H., Jin, Z., & Chi, Y. R. (2022) · Chem · doi:10.1016/j.chempr.2022.04.019 · Cited by 52
Targeting Iron in Colon Cancer via Glycoconjugation of Thiosemicarbazone Prochelators
Akam, E. A., & Tomat, E. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00332 · Cited by 54
Oliveri, V., Viale, M., Aiello, C., & Vecchio, G. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.09.017 · Cited by 47
Dyshlovoy, S. A., Pelageev, D. N., Hauschild, J., Borisova, K. L., Kaune, M., Krisp, C., Venz, S., Sabutskii, Y. E., Khmelevskaya, E. A., Busenbender, T., et al. (2019) · Cancers · doi:10.3390/cancers11111690 · Cited by 49
“Increased selectivity and efficacy can be achieved by linking cytotoxic anticancer drugs to specific target/carrier molecules [9].”
BackgroundInfluentialZheng, L., Gao, T., Ge, Z., Ma, Z., Xu, J., Ding, W., & Shen, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113226 · Cited by 47
Malinge, J., Géraudie, B., Savel, P., Nataf, V., Prignon, A., Provost, C., Zhang, Y., Ou, P., Kerrou, K., Talbot, J., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00794 · Cited by 47
Quinoxaline Moiety: A Potential Scaffold against Mycobacterium tuberculosis
Montana, M., Montero, V., Khoumeri, O., & Vanelle, P. (2021) · Molecules · doi:10.3390/molecules26164742 · Cited by 45
Tong, K., Wan, P., Lok, C., & Che, C. (2021) · Chemical Science · doi:10.1039/d1sc02841c · Cited by 46
Zhang, P., Ma, J., Zhang, Q., Jian, S., Sun, X., Liu, B., Nie, L., Liu, M., Liang, S., Zeng, Y., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00634 · Cited by 43
Boosting two-photon photodynamic therapy with mitochondria-targeting ruthenium–glucose conjugates
Liu, J., Liao, X., Xiong, K., Kuang, S., Jin, C., Ji, L., & Chao, H. (2020) · Chemical Communications · doi:10.1039/d0cc01148g · Cited by 44
Domiński, A., Krawczyk, M., Konieczny, T., Kasprów, M., Foryś, A., Pastuch-Gawołek, G., & Kurcok, P. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.07.019 · Cited by 46
Liu, R., Li, H., Gao, X., Mi, Q., Zhao, H., & Gao, Q. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.004 · Cited by 41
Harnessing GLUT1‐Targeted Pro‐oxidant Ascorbate for Synergistic Phototherapeutics
Koo, S., Lee, M., Sharma, A. K., Li, M., Zhang, X., Pu, K., Chi, S., & Kim, J. S. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202110832 · Cited by 45
Patra, M., Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Angewandte Chemie · doi:10.1002/ange.201510551 · Cited by 43
Parashar, P., Rana, P., Dwivedi, M., & Saraf, S. A. (2018) · Journal of Liposome Research · doi:10.1080/08982104.2018.1551408 · Cited by 41
“mon cancer in the world, with 630,000 new cases diagnosed each year (Calvaresi and Hergenrother 2013).”
BackgroundInfluentialMumcuoglu, D., Ekiz, M. Ş., Gunay, G., Tekinay, T., Tekinay, A. B., & Guler, M. O. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b01526 · Cited by 44
Wang, H., Simmons, C. J., Zhang, Y., Smits, A. M., Balzer, P. G., Wang, S., & Tang, W. (2017) · Organic Letters · doi:10.1021/acs.orglett.6b03683 · Cited by 40
Innovations in Nuclear Imaging Instrumentation: Cerenkov Imaging
Tamura, R., Pratt, E. C., & Grimm, J. (2018) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2018.02.007 · Cited by 40
Zuffo, M., Stucchi, A., Campos‐Salinas, J., Cabello‐Donayre, M., Martínez‐García, M., Belmonte‐Reche, E., Pérez-Victoria, J. M., Mergny, J., Freccero, M., Morales, J. C., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.043 · Cited by 42
Synthesis of new triazole linked carbohybrids with ROS-mediated toxicity in breast cancer
Kumari, P., Dubey, S., Venkatachalapathy, S., Narayana, C., Gupta, A. K., & Sagar, R. (2019) · New Journal of Chemistry · doi:10.1039/c9nj03288f · Cited by 40
Amphiphilic glycoconjugates as potential anti-cancer chemotherapeutics
Govindarajan, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.015 · Cited by 39
Prochelator strategies for site-selective activation of metal chelators
Oliveri, V., & Vecchio, G. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.05.012 · Cited by 42
Multicolor GLUT5-permeable fluorescent probes for fructose transport analysis
Begoyan, V., Weseliński, Ł. J., Xia, S., Fedie, J. R., Kannan, S., Ferrier, A., Rao, S., & Tanasova, M. (2018) · Chemical Communications · doi:10.1039/c7cc09809j · Cited by 38
Wang, C., Liu, L., Cao, H., & Zhang, W. (2016) · Biomaterials Science · doi:10.1039/c6bm00482b · Cited by 38
GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates
Liu, R., Fu, Z., Zhao, M., Gao, X., Li, H., Mi, Q., Liu, P., Yang, J., Yao, Z., & Gao, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.17073 · Cited by 41
“Novel strategies, such as glycoconjugation, for enhancing tumor-targeting properties of platinum anti-cancer complexes are of great interest and become an appealing strategy for targeted delivery [45, 46].”
BackgroundYang, Q., Cao, Q., Qin, Q., Deng, C.-X., Liang, H., & Chen, Z. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071874 · Cited by 37
Kowsalya, K., Vidya, N., Halka, J., Preetha, J. S. Y., Muthukrishnan, S., Sahayarayan, J. J., Gurusaravanan, P., & Arun, M. (2025) · Glycoconjugate Journal · doi:10.1007/s10719-025-10180-3 · Cited by 51
Annunziata, A., Cucciolito, M. E., Esposito, R., Imbimbo, P., Petruk, G., Ferraro, G., Pinto, V., Tuzi, A., Monti, D. M., Merlino, A., et al. (2019) · Dalton Transactions · doi:10.1039/c9dt01614g · Cited by 39
pH-Responsive Cascaded Nanocatalyst for Synergistic Like-Starvation and Chemodynamic therapy
Wang, Y., & Song, M. I. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111029 · Cited by 35
Pelageev, D. N., Dyshlovoy, S. A., Pokhilo, N. D., Денисенко, В. А., Borisova, K. L., Amsberg, G. K.-V., Bokemeyer, C., Fedorov, S. N., Honecker, F. U., & Ануфриев, В. Ф. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.006 · Cited by 35
“The idea of conjugating of anticancer agents with sugar residues is based on theWarburg effect [8,9].”
BackgroundNew emerging bio-catalysts design in biotransformations
Palomo, J. M., & Filice, M. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.12.010 · Cited by 35
Itoh, T., Tamura, K., Ueda, H., Tanaka, T., Sato, K., Kuroda, R., & Aoki, S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.10.041 · Cited by 35
Dyshlovoy, S. A., Pelageev, D. N., Hauschild, J., Sabutskii, Y. E., Khmelevskaya, E. A., Krisp, C., Kaune, M., Venz, S., Borisova, K. L., Busenbender, T., et al. (2020) · Marine Drugs · doi:10.3390/md18050251 · Cited by 34
“Targeting the Warburg effect is an interesting novel treatment approach utilizing an increased sugar uptake of cancer cells to incorporate sugar conjugated cytotoxic compounds into tumor cells [6,7].”
Background
Metadata
- Authors
- Calvaresi, E. C., & Hergenrother, P. J.
- Affiliations
- University of Illinois Urbana-Champaign (US)
- Corresponding author
- Hergenrother, Paul J.
- Venue
- Chemical Science
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2013
- Volume
- 4
- Issue
- 6
- Pages
- 2319
- ISSN
- 2041-6520 (ISSN-L)
- 2041-6539
- PMC
- PMC3784344
- OpenAlex
- W2110592482
- Cited by
- 398
- References
- 98
- Citations by year
- 2026: 16 · 2025: 42 · 2024: 29 · 2023: 32 · 2022: 41 · 2021: 24 · 2020: 42 · 2019: 43 · 2018: 32 · 2017: 28 · 2016: 40 · 2015: 17 · 2014: 10 · 2013: 2
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Chemical Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- U.S. Food and Drug Administration
- University of Illinois at Urbana-Champaign
- National Cancer Institute (F30CA168323)
- National Institute of General Medical Sciences (R01GM098453)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- glycoconjugates, glucose conjugation, tumor targeting, Warburg effect, aerobic glycolysis, cytotoxin, cancer metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.